IP Library Granted Patent US 11,547,783
Granted Patent B2
US 11,547,783 · App. 15/532,582 · Granted Jan 10, 2023

Blood filter

Inventors: Alan Christopher Spivey (London, GB); Gregory John Quinlan (London, GB); Nathan Davies (London, GB)
Assignees: IMPERIAL COLLEGE INNOVATIONS LIMITED; UCL BUSINESS LTD
A61M1/0218A61M1/0259A61M1/3486A61M1/362A61M1/3633A61M1/3679A61M1/3687A61M1/38A61M1/88
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,547,783
App. No.
15/532,582
Granted
Jan 10, 2023
Kind
B2
Abstract

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

Claims (26)

1. A device for removal of haemolysis-derived components from blood, the device comprising:

a support, and

a plurality of binding agents bound to said support,

wherein the binding agents comprise at least one iron-chelating molecule, at least one haemoglobin-binding molecule, and at least one haem-binding molecule,

wherein the haemoglobin-binding molecule, the haem-binding molecule, and the iron-chelating molecule are present in the respective proportions 50-90%, 5-50% and 1-30% of the binding agents bound to the support, such that the sum of the proportions equals 100% of the binding agents bound to the support, and

whereby the at least one iron-chelating molecule, the at least one haemoglobin-binding molecule, and the at least one haem-binding molecule are able to bind and to remove out of solution haemolysis-derived iron, haemoglobin, and haem, respectively, from blood contacted with the device, wherein the haemolysis from which the iron, haemoglobin and haem are derived occurred in the blood contacted with the device.

2. A device according to claim 1 further comprising a vessel for the storage or passage of blood, wherein the vessel contains the support.

3. A device according to claim 2 , wherein the support is wholly or partially integrated with the vessel.

4. A device according to claim 2 , wherein the support is not integrated with the vessel.

5. A device according to claim 1 , wherein the support is a plurality of beads.

6. A device according to claim 5 , wherein each bead of the plurality of beads is bound to no more than one of: the iron-chelating molecule, the haemoglobin-binding molecule, and the haem-binding molecule.

7. A device according to claim 1 , wherein the support is a single element to which at least one iron-chelating molecule, at least one haemoglobin-binding molecule, and at least one haem-binding molecule are bound.

8. A device according to claim 1 , wherein the support comprises an insoluble polymer or a glass.

9. A device according to claim 1 , wherein the iron-chelating molecule is desferrioxamine, the haemoglobin-binding molecule is haptoglobin, and the haem-binding molecule is serum albumin.

10. A device according to claim 1 , wherein the device is for in vitro or ex vivo removal of haemolysis-derived components from blood.

11. A device according to claim 1 wherein the device is a component of an extracorporeal blood circulation apparatus or an apparatus comprising a flow line for delivering blood from a blood bag to a patient.

12. A method for removing haemolysis-derived components from a blood sample, the method comprising applying the blood sample to a device according to claim 1 , wherein the at least one iron-chelating molecule, the at least one haemoglobin-binding molecule, and the at least one haem-binding molecule remove haemolysis-derived iron, haemoglobin and haem, respectively, from the blood sample applied to the device.

13. A method according to claim 12 wherein the device is a component of an extracorporeal blood circulation apparatus or an apparatus comprising a flow line for delivering blood from a blood bag to a patient.

14. A method of treating or preventing haemolysis-associated pathology in a subject, the method comprising applying blood from a subject to a device according to claim 1 such that the at least one iron-chelating molecule, the at least one haemoglobin-binding molecule, and the at least one haem-binding molecule bind and remove out of solution haemolysis-derived iron, haemoglobin and haem, respectively, from the blood applied to the device, and administering said blood to a subject, such that haemolysis-associated pathology as a result of the blood being administered is reduced.

15. A method according to claim 14 wherein the device is a component of an extracorporeal blood circulation apparatus or an apparatus comprising a flow line for delivering blood from a blood bag to a patient.

16. A device according to claim 1 , wherein the support is a single element to which the at least one iron-chelating molecule, the at least one haemoglobin-binding molecule, and the at least one haem-binding molecule are bound, wherein all of the plurality of binding agents are bound to the single element.

17. A device according to claim 1 wherein the support comprises an insoluble polymer that is agarose or a PEGylated synthetic polymer.

18. A device according to claim 1 , further comprising a vessel for the storage or passage of blood, wherein the vessel contains the support;

wherein the support is a single element to which at least one iron-chelating molecule, at least one haemoglobin-binding molecule, and at least one haem-binding molecule are bound; and

wherein the support is not integrated with the vessel.

19. A method according to claim 14 wherein the subject from which the blood is taken and the subject to which the blood is administered is the same subject.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ZIP CODE PREVIOUSLY RECORDED AT REEL: 055027 FRAME: 0470. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 12, 2021
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 056166/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: IMPERIAL INNOVATIONS LIMITED
To: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Reel/Frame 054953/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2021
From: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
To: IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 054953/0178 →
CHANGE OF NAME Recorded Jan 19, 2021
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 055027/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: SPIVEY, ALAN CHRISTOPHER; QUINLAN, GREGORY JOHN
To: IMPERIAL INNOVATIONS LIMITED
Reel/Frame 053999/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: DAVIES, NATHAN
To: UCL BUSINESS PLC
Reel/Frame 053999/0242 →
Priority Claims (1)
GB 1421403 · Dec 2, 2014 · national
Continuity (1)
Related Publication 20180015211A1 · Jan 18, 2018